New drug duo aims to wipe out leukemia cells in First-Line treatment
NCT ID NCT07557056
First seen Jun 27, 2026 · Last updated Jul 01, 2026 · Updated 1 time
Summary
This phase 2 trial tests two oral drugs, nemtabrutinib and venetoclax, as a first treatment for people with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL). The goal is to see if the combination can make cancer cells undetectable in the blood. About 25 adults who have not had prior treatment will take the drugs for 14 cycles, and researchers will check for side effects and how well the cancer responds.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
nemtabrutinib and venetoclax
What this could lead to
If successful, this combination could offer a highly effective frontline treatment for CLL/SLL, potentially achieving deep remission with undetectable cancer cells.
What could go wrong
This is a small, early-phase trial with only 25 participants. The combination may cause side effects, and results may not generalize to all patients. It is not yet recruiting.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CHRONIC LYMPHOCYTIC LEUKEMIA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Ohio State University Comprehensive Cancer Center
Columbus, Ohio, 43210, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact